Breaking News & Company Info
Get access to Genentech information and resources for stories in development. Find recent and archived press releases.
FDA Approval: Personalized Medicine for a Specific Type of Metastatic Non-Small Cell Lung Cancer (NSCLC) as Detected by an FDA-Approved Test
On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.
Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.
On February 22nd, 2013, the FDA approved a new personalized Genentech medicine for people with an aggressive form of breast cancer.
On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.
On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.
gRide, Genentech's employee commuting program, has now saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus, and since has had significant impact on Genentech's sustainability goals and employee quality of life.
gOn August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).